Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

PURPOSE: The aurora A kinase inhibitor alisertib demonstrated single-agent clinical activity and preclinical synergy with vincristine/rituximab in B-cell non-Hodgkin lymphoma (B-NHL). This phase I study aimed to determine the safety and recommended phase II dose (RP2D) of alisertib in combination wi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Kelly, Kevin R., Friedberg, Jonathan W., Park, Steven I., McDonagh, Kevin, Hayslip, John, Persky, Daniel, Ruan, Jia, Puvvada, Soham, Rosen, Peter, Padmanabhan Iyer, Swaminathan, Stefanovic, Alexandra, Bernstein, Steven H., Weitman, Steven, Karnad, Anand, Monohan, Gregory, VanderWalde, Ari, Mena, Raul, Schmelz, Monika, Spier, Catherine, Groshen, Susan, Venkatakrishnan, Karthik, Zhou, Xiaofei, Sheldon-Waniga, Emily, Leonard, E. Jane, Mahadevan, Daruka
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7731903/
https://ncbi.nlm.nih.gov/pubmed/30082475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0286
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados